Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series F round brings in $14mm for SynCardia Systems

Executive Summary

Cardiovascular device developer SynCardia Systems Inc. raised $14mm through what is believed to be its Series F venture round. Returning shareholder Athyrium Capital Management invested $4mm and SWK Holding provided the remainder. The money will be used to continue developing and launch a smaller version (50cc vs. 70cc) of the SynCardia Total Artificial Heart, the first and only FDA- and Health Canada-approved and CE-Marked total artificial heart. Some funds will also be used to make the Freedom portable driver (which powers the SynCardia systems) available and to use SynCardia’s technology for destination therapy. Wedbush PacGrow Life Sciences was the placement agent.

Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies